Cargando…

Tivozanib in the treatment of renal cell carcinoma

Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemotherapy. Interferon-α and interleukin-2 were previously utilized in a limited number of patients with good performance status du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hepgur, Mehmet, Sadeghi, Sarmad, Dorff, Tanya B, Quinn, David I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684142/ https://www.ncbi.nlm.nih.gov/pubmed/23788831 http://dx.doi.org/10.2147/BTT.S32958

Ejemplares similares

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
por: Westerman, Mary E., et al.
Publicado: (2020)

EphrinB2: Expression of a novel potential target in renal cell carcinoma
por: Gupta, Chhavi, et al.
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review
por: Vashistha, Vishal, et al.
Publicado: (2014)

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Immune Response to Sipuleucel-T in Prostate Cancer
por: Thara, Eddie, et al.
Publicado: (2012)

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer
por: Dorff, Tanya B, et al.
Publicado: (2018)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
por: Lyou, Yung, et al.
Publicado: (2021)

New treatment modalities with vaccine therapy in renal cell carcinoma
por: Sönmez, Mehmet Giray, et al.
Publicado: (2019)

Fasting and cancer treatment in humans: A case series report
por: Safdie, Fernando M., et al.
Publicado: (2009)

Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer
por: Ramshankar, Vijayalakshmi, et al.
Publicado: (2014)

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
por: Kalathil, Suresh Gopi, et al.
Publicado: (2020)

Treatment of Refractory Metastatic Renal Cell Carcinoma
por: Vento, Joseph A., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer
por: Gross, Mitchell E., et al.
Publicado: (2020)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

An Update on the Treatment of Papillary Renal Cell Carcinoma
por: Chawla, Neal S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lk43v9vfe2qfrf4pian15iu6ie